Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson�s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.